Minireviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 26, 2022; 10(30): 10852-10861
Published online Oct 26, 2022. doi: 10.12998/wjcc.v10.i30.10852
Hyperthermic intraperitoneal chemotherapy and colorectal cancer: From physiology to surgery
Giorgio Ammerata, Rosalinda Filippo, Carmelo Laface, Riccardo Memeo, Leonardo Solaini, Davide Cavaliere, Giuseppe Navarra, Girolamo Ranieri, Giuseppe Currò, Michele Ammendola
Giorgio Ammerata, Rosalinda Filippo, Giuseppe Currò, Michele Ammendola, Science of Health Department, Digestive Surgery Unit, University “Magna Graecia” Medical School, Catanzaro 88100, Italy
Carmelo Laface, Girolamo Ranieri, Interventional Oncology Unit with Integrated Section of Translational Medical Oncology, National Cancer Research Centre “Giovanni Paolo II”, Bari 70124, Italy
Riccardo Memeo, Hepato-Biliary and Pancreatic Surgical Unit, “F. Miulli” Hospital, Acquaviva delle Fonti, Bari 70124, Italy
Leonardo Solaini, Department of Medical and Surgical Sciences, University of Bologna, Forlì 40126, Italy
Davide Cavaliere, Department of General and Oncologic Surgery, Morgagni-Pierantoni Hospital, Forlì 47121, Italy
Giuseppe Navarra, Department of Human Pathology of Adult and Evolutive Age, Surgical Oncology Division, “G. Martino” Hospital, University of Messina, Messina 98122, Italy
Author contributions: Ammerata G and Ammendola M contributed to the study design; Filippo R, Memeo R, Laface C, and Solaini L contributed to the data collection and statistical analysis; Cavaliere D and Navarra G contributed to drafting and revising the manuscript critically; Ranieri G, Currò G, and Ammendola M contributed to the final approval of the version submitted.
Conflict-of-interest statement: The authors have nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Michele Ammendola, MD, PhD, Professor, Science of Health Department, Digestive Surgery Unit, University “Magna Graecia” Medical School, Viale Europa, Germaneto, Catanzaro 88100, Italy. michele.ammendola@unicz.it
Received: January 13, 2022
Peer-review started: January 13, 2022
First decision: June 15, 2022
Revised: June 23, 2022
Accepted: August 13, 2022
Article in press: August 13, 2022
Published online: October 26, 2022
Abstract

The pursuit of this paper is to collect principal reviews and systematic reviews about hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) used in colorectal cancer (CRC). We focus on principal biological aspects of CRC, hyperthermia effects, and surgical procedures. We searched PubMed/MEDLINE for the principal reviews and systematic reviews published from 2010 to 2021 regarding the bimodal treatment (CRS + HIPEC) against local and advanced CRC. In the literature, from several studies, it seems that the efficacy of bimodal treatment with an accurate CRS can extend overall survival. Despite these studies, there are not still any straight guidelines more detailed and scheduled about the use of combined treatment in patients with CRC. Even if the concept is still not very clear and shared, after a careful evaluation of the published data, and after some technical and pathophysiological descriptions, we concluded that it is possible to improve the overall survival and quality of life and to reduce the tumor relapse in patients affected by locally advanced (pT4) CRC with peritoneal metastases.

Keywords: Hyperthermic intraperitoneal chemotherapy, Colorectal cancer, Peritoneum, Cytoreductive surgery

Core Tip: The purpose of this review is to summarize the most relevant evidence on the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer and to specify the main properties of HIPEC and its application.